OUTLOOK THERAPEUTICS, INC. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
OUTLOOK THERAPEUTICS, INC. (OTLK) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of $791.67 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-18.
Financial Statements › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-18
- OUTLOOK THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was $791.67K, a 52.94% decline year-over-year.
- OUTLOOK THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $757.48K, a 56.03% decline year-over-year.
- OUTLOOK THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-12-31 was $881.15K, a 76.01% decline year-over-year.
- OUTLOOK THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-06-30 was $1.68M, a 20.47% increase year-over-year.
- OUTLOOK THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2025 was $8.90M, a 65.23% increase from fiscal 2024.
- OUTLOOK THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2024 was $5.39M, a 2.92% decline from fiscal 2023.
- OUTLOOK THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $5.55M, a 28.06% decline from fiscal 2022.
- OUTLOOK THERAPEUTICS, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2022 was $7.71M, a 57.77% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month as first filed | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $791.67K 10-Q · filed 2026-08-18 | $1.55M derived: sum of 2 quarters · filed 2026-08-18 | $2.43M derived: sum of 3 quarters · filed 2026-08-18 | |||
| 2026-03-31 | $757.48K 10-Q · filed 2026-08-18 | $1.64M derived: sum of 2 quarters · filed 2026-08-18 | ||||
| 2025-12-31 | $881.15K 10-Q · filed 2026-08-18 | |||||
| 2025-09-30 | $8.90M 10-K · filed 2025-12-19 | |||||
| 2025-06-30 | $1.68M 10-Q · filed 2026-08-18 | $3.40M derived: sum of 2 quarters · filed 2026-08-18 | $7.08M derived: sum of 3 quarters · filed 2026-08-18 | |||
| 2025-03-31 | $1.72M 10-Q · filed 2026-08-18 | $5.40M derived: sum of 2 quarters · filed 2026-08-18 | ||||
| 2024-12-31 | $3.67M 10-Q · filed 2026-08-18 | |||||
| 2024-09-30 | $5.39M 10-K · filed 2025-12-19 | |||||
| 2024-06-30 | $1.40M 10-Q · filed 2025-08-14 | $2.71M derived: sum of 2 quarters · filed 2025-08-14 | $3.98M derived: sum of 3 quarters · filed 2025-08-14 | |||
| 2024-03-31 | $1.31M 10-Q · filed 2025-08-14 | $2.58M derived: sum of 2 quarters · filed 2025-08-14 | ||||
| 2023-12-31 | $1.27M 10-Q · filed 2025-08-14 | |||||
| 2023-09-30 | $5.55M 10-K · filed 2024-12-27 | |||||
| 2023-06-30 | $1.38M 10-Q · filed 2024-08-14 | $2.77M derived: sum of 2 quarters · filed 2024-08-14 | $4.16M derived: sum of 3 quarters · filed 2024-08-14 | |||
| 2023-03-31 | $1.38M 10-Q · filed 2024-08-14 | $2.78M derived: sum of 2 quarters · filed 2024-08-14 | ||||
| 2022-12-31 | $1.39M 10-Q · filed 2024-08-14 | |||||
| 2022-09-30 | $7.71M 10-K · filed 2023-12-22 | |||||
| 2022-06-30 | $1.37M 10-Q · filed 2023-08-14 | $5.13M derived: sum of 2 quarters · filed 2023-08-14 | $6.33M derived: sum of 3 quarters · filed 2023-08-14 | $7.74M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | $3.76M 10-Q · filed 2023-08-14 | $4.97M derived: sum of 2 quarters · filed 2023-08-14 | $6.37M derived: sum of 3 quarters · filed 2023-08-14 | $7.57M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2021-12-31 | $1.20M 10-Q · filed 2023-08-14 | $2.61M derived: sum of 2 quarters · filed 2023-08-14 | $3.81M derived: sum of 3 quarters · filed 2023-08-14 | $4.94M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2021-09-30 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2022-12-29 | $2.60M derived: sum of 2 quarters · filed 2022-12-29 | $3.73M derived: sum of 3 quarters · filed 2022-12-29 | $4.89M 10-K · filed 2022-12-29 | ||
| 2021-06-30 | $1.20M 10-Q · filed 2022-08-10 | $2.33M derived: sum of 2 quarters · filed 2022-08-10 | $3.48M 10-Q · filed 2021-08-13 | $4.27M derived: sum of 4 quarters · filed 2022-08-10 | ||
| 2021-03-31 | $1.13M 10-Q · filed 2022-08-10 | $2.28M 10-Q · filed 2021-05-14 | $3.07M derived: sum of 3 quarters · filed 2022-08-10 | $4.43M derived: sum of 4 quarters · filed 2022-08-10 | ||
| 2020-12-31 | $1.15M 10-Q · filed 2022-08-10 | $1.94M derived: sum of 2 quarters · filed 2022-08-10 | $3.30M derived: sum of 3 quarters · filed 2022-08-10 | $3.60M derived: sum of 4 quarters · filed 2022-08-10 | ||
| 2020-09-30 | $784.69K derived: 10-K 12 month − 10-Q 9 month · filed 2021-12-23 | $2.14M derived: sum of 2 quarters · filed 2021-12-23 | $2.45M derived: sum of 3 quarters · filed 2021-12-23 | $2.81M 10-K · filed 2021-12-23 | ||
| 2020-06-30 | $1.36M 10-Q · filed 2021-08-13 | $1.66M derived: sum of 2 quarters · filed 2021-08-13 | $2.02M 10-Q · filed 2021-08-13 | $2.23M derived: sum of 4 quarters · filed 2021-08-13 | ||
| 2020-03-31 | $304.54K 10-Q · filed 2021-05-14 | $664.02K 10-Q · filed 2021-05-14 | $868.59K derived: sum of 3 quarters · filed 2021-05-14 | $837.32K derived: sum of 4 quarters · filed 2021-05-14 | ||
| 2019-12-31 | $359.48K 10-Q · filed 2021-02-16 | $564.05K derived: sum of 2 quarters · filed 2021-02-16 | $532.78K derived: sum of 3 quarters · filed 2021-02-16 | $800.52K derived: sum of 4 quarters · filed 2021-02-16 | ||
| 2019-09-30 | $204.57K derived: 10-K 12 month − 10-Q 9 month · filed 2020-12-23 | $173.30K derived: sum of 2 quarters · filed 2020-12-23 | $441.05K derived: sum of 3 quarters · filed 2020-12-23 | $1.31M 10-K · filed 2020-12-23 | ||
| 2019-06-30 | -$31.27K 10-Q · filed 2020-08-14 | $236.48K derived: sum of 2 quarters · filed 2020-08-14 | $1.11M 10-Q · filed 2020-08-14 | $1.27M derived: sum of 4 quarters · filed 2020-08-14 | ||
| 2019-03-31 | $267.74K 10-Q · filed 2020-05-15 | $1.14M 10-Q · filed 2020-05-15 | $1.19M 10-Q · filed 2019-05-15 | $1.30M derived: sum of 3 quarters · filed 2020-05-15 | $1.54M derived: sum of 4 quarters · filed 2020-05-15 | |
| 2018-12-31 | $872.29K 10-Q · filed 2020-02-14 | $921.41K 10-Q · filed 2019-02-14 | $1.03M derived: sum of 2 quarters · filed 2020-02-14 | $1.27M derived: sum of 3 quarters · filed 2020-02-14 | $968.34K derived: sum of 4 quarters · filed 2020-02-14 | |
| 2018-09-30 | $162.14K derived: 10-K 12 month − 10-Q 9 month · filed 2019-12-19 | $396.26K derived: sum of 2 quarters · filed 2019-12-19 | $96.05K derived: sum of 3 quarters · filed 2019-12-19 | $1.99M 10-K · filed 2019-12-19 | ||
| 2018-06-30 | $234.12K 10-Q · filed 2019-08-14 | -$66.09K derived: sum of 2 quarters · filed 2019-08-14 | $1.82M 10-Q · filed 2019-08-14 | $3.48M derived: sum of 4 quarters · filed 2019-08-14 | ||
| 2018-03-31 | -$300.21K 10-Q · filed 2019-05-15 | $1.59M 10-Q · filed 2019-05-15 | $3.25M derived: sum of 3 quarters · filed 2019-05-15 | $5.37M derived: sum of 4 quarters · filed 2019-05-15 | ||
| 2017-12-31 | $1.89M 10-Q · filed 2019-02-14 | $3.55M derived: sum of 2 quarters · filed 2019-02-14 | $5.67M derived: sum of 3 quarters · filed 2019-02-14 | $8.00M derived: sum of 4 quarters · filed 2019-02-14 | ||
| 2017-09-30 | $1.66M derived: 10-K 12 month − 10-Q 9 month · filed 2018-12-18 | $3.78M derived: sum of 2 quarters · filed 2018-12-18 | $6.11M derived: sum of 3 quarters · filed 2018-12-18 | $8.57M 10-K · filed 2018-12-18 | ||
| 2017-06-30 | $2.12M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-08-14 | $4.45M derived: sum of 2 quarters · filed 2017-08-14 | $6.91M 10-Q · filed 2017-08-14 | $10.74M derived: sum of 4 quarters · filed 2017-12-29 | ||
| 2017-03-31 | $2.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-05-15 | $4.79M 10-Q · filed 2017-05-15 | $8.62M derived: sum of 3 quarters · filed 2017-12-29 | $19.20M derived: sum of 4 quarters · filed 2017-12-29 | ||
| 2016-12-31 | $2.46M 10-Q · filed 2017-02-14 | $6.30M derived: sum of 2 quarters · filed 2017-12-29 | $16.87M derived: sum of 3 quarters · filed 2017-12-29 | |||
| 2016-09-30 | $3.83M derived: 10-K 12 month − 10-Q 9 month · filed 2017-12-29 | $14.41M derived: sum of 2 quarters · filed 2017-12-29 | $10.06M 10-K · filed 2017-12-29 | |||
| 2016-06-30 | $10.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-08-15 | $6.23M 10-Q · filed 2016-08-15 | ||||
| 2016-03-31 | -$4.35M 10-Q · filed 2016-06-27 | |||||
| 2015-09-30 | $8.93K 10-K · filed 2016-12-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |